What does a psoriasis trial actually measure?
A trial does not report skin. It reports a named endpoint, agreed before the study ran. Most psoriasis trials name a score, a bar and a week. The three together are the result. Evidence Evidence Evidence Evidence
What is known
- Reasonably supported
I read the 1978 paper that first set out the Psoriasis Area and Severity Index. A trial names a response by how far that score fell. One review of light treatment reports its pooled result that way, as a PASI 75 rate. The International Psoriasis Council pairs body surface area with a doctor rating. The Dermatology Life Quality Index is a short form you fill in. It records life impact, not how the skin looks. People I have heard from ask whether a treatment will clear them, and what it will cost them in side effects.
What is uncertain
- Depends on you
What that means for you is that the endpoint sets the story. A study can move a skin score and barely move a life score. It can also do the reverse. I set out what each score measures on how severe is yours. How to read your own change over weeks is on measuring change. A group result at a set week is not a forecast for one person.
Questions to ask about the research
Which score did this study use, and which bar did it report?
Saving keeps this on your device and needs JavaScript, which is off in this browser.At which week was my kind of response measured?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Why do two trials of the same treatment report different clear-skin numbers?
Because they are rarely the same question. The bar can differ, the week can differ, and the comparison can differ. A treatment tested against a dummy treatment and a treatment tested against another active drug produce numbers that cannot be lined up. Evidence Evidence
What is known
- Reasonably supported
I read the skin of colour review, which pooled nine studies of narrowband UVB. It reports a PASI 75 rate of 70.5 per cent. The 95 per cent confidence interval runs from 65 to 75 per cent. One study inside that review reached 93.3 per cent target plaque clearance by twelve weeks. In that study, light was paired with a topical treatment. CONSORT 2025 asks a trial report to state its design, participants, treatments, outcomes, harms and analysis.
What is uncertain
- Depends on you
What that means for you is that two numbers line up only when the bar, the week and the comparison match. CONSORT is a reporting guide, not a quality score. A confidence interval shows the range the data support. The single best number inside it is still an estimate. How I read a study is set out on the research method page.
Questions to ask about the research
Was this treatment compared against a dummy treatment or against another drug?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Does that comparison change how I should read the percentage?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Were people with skin like mine in the study?
Check before you read the result. Enrollment in psoriasis research is often narrow, and a missing group is common enough to look for first. Evidence Evidence
What is known
- Reasonably supported
The skin of colour review covered about 1,334 people. Their skin was Fitzpatrick type III through V, and most were from Asia. It reports no results for Fitzpatrick I and II skin. It records darker patches after treatment as a concern in darker skin. It notes that redness can be harder to see in some skin of colour patients. Side effects may then be under-reported. FDA guidance asks study sponsors to plan who gets enrolled, and to set goals in writing for groups left out in the past.
What is uncertain
- Depends on you
What that means for you is that a gap limits the reading rather than settling it. A group left out is a group the study cannot speak for, either way. The FDA text is draft, non-binding guidance. Who was studied goes deeper into this check.
Questions to ask about the research
Did this study report skin tone, and were my skin type and my ancestry represented?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Does under-reported redness change how you would watch me for side effects?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
How does a pile of trials become a recommendation?
A guideline panel grades the body of evidence, then writes a recommendation with a letter or a strength attached. The letter describes the evidence behind the advice, not how well it will suit you. Evidence Evidence Evidence Evidence Evidence
What is known
- Reasonably supported
I checked the joint AAD and NPF light guideline, which gives narrowband UVB on its own a grade A rating in adults with plaque psoriasis. The joint systemic guideline records a set of whole-body options used in psoriasis care. The joint comorbidities guideline covers psoriasis beside joint disease, heart disease, obesity, raised blood pressure, raised blood fats, diabetes and bowel disease. NICE covers checks on skin, nails, high-impact sites, life impact and joints. The International Psoriasis Council replaced the old severity scale with two groups.
What is uncertain
- Depends on you
What that means for you is that a grade rates the evidence, not the fit. Guideline authors report ties to industry. NICE is UK guidance and sets no US order of treatment. The council statement is a shared expert view. None of them picks a treatment for one person.
Questions to ask about the research
Which guideline are you working from for my psoriasis?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Where do I sit against the criteria that guideline uses?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What can a trial not tell me?
A trial runs for a set time in a picked group. So it answers a short question well and a long one poorly. Rare harms and years of use sit outside it. The record keeps changing after a product reaches the market. Evidence Evidence Evidence
What is known
- Reasonably supported
FDA splits drug work into five stages. They are discovery, lab research, trials in people, FDA review, and watching the product once it is sold. Label text carries a revision date. I checked the oral psoriasis label registered here, and it was revised in March 2026. The skin of colour review reports no data on skin cancer risk, and none on long-term safety tracking.
What is uncertain
- Depends on you
What that means for you is that a label and a guideline keep changing, so the version matters. The FDA page is a high-level overview, not a verdict on any product. A label is approved text for one product, not a comparison. The glossary defines the terms a label and a trial report use.
Questions to ask about the research
What is known about this treatment over years rather than weeks?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Has the label or the guidance for it changed since you last reviewed it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
How do you bring a paper to your dermatologist?
Bring the study itself, not the article about it. Note the endpoint, the week, the comparison and who was enrolled. Then bring your own record, so the two can be set side by side. Evidence Evidence
What is known
- Reasonably supported
The National Psoriasis Foundation backs bringing a symptom tracker to a visit. It can be kept on paper or on a phone, and shared with the doctor. It also backs describing symptoms clearly, and noting changes in how bad the skin is and where. CONSORT 2025 names the parts of a trial report to look for. Those parts are design, participants, treatments, outcomes, harms and analysis.
What is uncertain
- Depends on you
What that means for you is that a prepared question changes the talk, not the evidence. A paper is one input beside your history, your other health conditions and what you have tried. When a claim comes from a seller rather than a journal, evaluating claims and miracle cures is the page for it. Joining a psoriasis clinical trial covers what a study itself asks of you.
Questions to ask about the research
Does this study match my psoriasis closely enough to change my plan?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would you want to see before moving me to the treatment in it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary I reviewed as of 2026-09-19.
- What this evidence supports
- I read the 1978 paper that first set out the Psoriasis Area and Severity Index. A trial names a response by how far that score fell. One review of light treatment reports its pooled result that way, as a PASI 75 rate. The International Psoriasis Council pairs body surface area with a doctor rating. The Dermatology Life Quality Index is a short form you fill in. It records life impact, not how the skin looks. People I have heard from ask whether a treatment will clear them, and what it will cost them in side effects.
- What it does not establish
- What that means for you is that the endpoint sets the story. A study can move a skin score and barely move a life score. It can also do the reverse. I set out what each score measures on how severe is yours. How to read your own change over weeks is on measuring change. A group result at a set week is not a forecast for one person.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- The BMJ (Hopewell S, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports transparent reporting of randomized-trial design, participants, interventions, outcomes, harms, analysis and participant flow so applicability and missing information can be assessed.
What it does not support
It is a reporting guideline, not a quality score, proof that a report is complete or evidence that a Vitiligo intervention works.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the importance of planning enrollment for populations historically underrepresented in clinical studies and making enrollment goals explicit.
What it does not support
It is draft, nonbinding guidance restored with a federal-site notice; it does not describe representation in any particular Vitiligo trial or prove applicability to an unstudied group.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the distinction between discovery, preclinical research, clinical research, FDA review and post-market monitoring in U.S. product development.
What it does not support
It is a high-level process overview, not a verdict on a specific emerging therapy, a statement that every research stage succeeds or a substitute for the current product label.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- International Psoriasis CouncilGuideline · Clinical research, tier 2Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The International Psoriasis Council names its corporate members on its own site (psoriasiscouncil.org/about/corporate-members/, checked 2026-09-11). The top tier names AbbVie, Johnson & Johnson, Eli Lilly, Novartis and Takeda. LEO Pharma, UCB, Almirall, Sun Pharma, Amgen, Alumis, Arcutis and Oruka sit below them. Those firms make the drugs this severity rule opens the door to. A wider rule on who qualifies is a wider market for them. The page says nothing about how that money relates to IPC independence.
What this source supports
Supports that IPC dropped the mild, moderate and severe scale. In its place a person is a candidate for topical therapy, or a candidate for systemic therapy. Supports that any one of three criteria is enough to be a candidate for systemic therapy. The first is psoriasis on 10% or more of the body surface. The second is psoriasis on a high-impact site. IPC names those sites as the face, palms, soles, genitalia, scalp and nails. The third is failure of topical therapy. Supports that IPC defines that failure in writing. It is not reaching clear or almost-clear skin after two four-week courses in a row. IPC gives clear or almost-clear as 1% or less body surface, with a physician global assessment of 0 or 1. Supports the source paper. It is Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020 Jan;82(1):117-122. Supports that IPC's own June 2025 teaching deck lists payers among the groups it set out to move. That deck also names refusal to pay as a result of the older scale.
What it does not support
Does not set any health plan's coverage rule. This is a professional-society consensus. It is not a regulation and not a plan document. Does not say which systemic treatment follows once a person meets a criterion. It sets no dose, no frequency and no schedule. Does not give the number of experts who voted, the response rate, or their conflict-of-interest disclosures. IPC's own June 2025 deck states the body-surface threshold two ways. Its criteria summary says 10% or more. The slide expanding that criterion says above 10%. Does not establish that a given reader meets a criterion. It predicts nothing about what a plan will decide.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the American Academy of Dermatology (Elmets CA, Leonardi CL, Davis DMR, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The guideline reports author relationships with industry. It is expert guidance, not independent proof for one person.
What this source supports
Supports that this guideline covers psoriasis alongside other health conditions. Supports naming psoriatic arthritis as one of them. Supports naming heart and blood vessel disease. Supports naming obesity, high blood pressure, raised blood fats and diabetes. Supports naming inflammatory bowel disease. Supports naming uveitis, an inflammation inside the eye. Supports naming depression and anxiety. Supports that it asks clinicians to screen people with psoriasis for psoriatic arthritis. Supports that it asks them to check heart risk factors. Supports naming body weight, blood pressure, blood fats and blood sugar among those checks. Supports that it asks them to screen for depression.
What it does not support
Does not diagnose a reader. Does not say which linked condition one person will get. Does not read a test result or set a personal plan. Its authors report industry relationships. It is US guidance. It does not set practice in another country.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing a symptom tracker, kept on paper or on a phone, to share with a doctor at an appointment. Supports clearly describing symptoms and noting changes in severity and affected areas as part of preparing for a visit.
What it does not support
Does not mention photographing skin changes specifically. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Dermatologica 1978;157(4):238-244 (Fredriksson T, Pettersson U)Observational study · Supporting research, tier 3Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: This 1978 paper is the first description of the Psoriasis Area and Severity Index. It is not open access. Any funding or competing-interest statement could not be read, and the study itself tested a drug.
What this source supports
Supports that the Psoriasis Area and Severity Index was first described here. Supports that the index scores three features of the skin: redness, thickness and scale. Supports that each of the three is graded on a scale of 0 to 4. Supports that the amount of skin involved is graded separately, on a scale of 0 to 6. Supports that the body is divided into four regions: the head, the upper limbs, the trunk and the lower limbs. Supports that each region carries its own weight, because each holds a different share of the skin. Supports that the four region scores are added, and that the total runs from 0 to 72.
What it does not support
Does not report how closely two clinicians scoring the same skin agree. Does not say how the redness grade behaves on brown or black skin. Does not set a score at which a person qualifies for any treatment. Does not say which health plans ask for the score. Does not diagnose a reader or predict what one person will score.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Clinical and Experimental Dermatology 1994;19(3):210-216 (Finlay AY, Khan GK)Observational study · Supporting research, tier 3Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: This 1994 paper is the first description of the Dermatology Life Quality Index. It is not open access, so any funding or competing-interest statement could not be read.
What this source supports
Supports that the Dermatology Life Quality Index was first described here. Supports that it is a ten-question form a person fills in themselves. Supports that every question asks about the last seven days. Supports that it was designed to be quick, and to be used in a routine clinic. Supports that the questions cover symptoms and feelings, daily activities, leisure, work or study, personal relationships, and the trouble of the treatment itself. Supports that each answer scores 0 to 3, and that the total runs from 0 to 30. Supports that a higher total means a heavier effect on life.
What it does not support
Is a first validation of a questionnaire, not a study of psoriasis treatment. Does not set a score at which a person qualifies for any treatment. Does not say which health plans ask for the score. A form about one week does not capture a better or worse week. Does not diagnose a reader or predict what one person will score.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: FDA-approved prescribing information is authoritative for US labeling; it is product-specific regulator-approved labeling, not independent comparative clinical evidence.
What this source supports
Supports the current FDA-approved labeled plaque-psoriasis population, oral route, IL-23 receptor mechanism, and label precautions for Icotyde (icotrokinra).
What it does not support
The label states only “Revised: 3/2026”; it does not establish an exact revision day or the approval-action date. It also does not establish comparative superiority, personal suitability, insurance coverage, mature postmarketing evidence, or a class-wide conclusion. SteadySkin does not reproduce its regimen.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The guideline reports author relationships; it is not independent comparative proof for an individual choice.
What this source supports
Supports that methotrexate, apremilast, cyclosporine and acitretin are established systemic nonbiologic options considered in psoriasis care.
What it does not support
It does not select, rank or prescribe an option for an individual reader.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the American Academy of Dermatology (Elmets CA, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: A joint guideline from a specialty society and a patient group. Authors report their own conflicts in the published article. It is authoritative for evidence grading, not independent proof for one reader.
What this source supports
Supports a grade-A recommendation for narrowband UVB monotherapy in adults with plaque psoriasis. Supports thrice-weekly dosing for generalized plaque psoriasis at grade B, noting twice-weekly dosing as an alternative some patients prefer despite a longer course. Supports that patients receiving twice-weekly narrowband UVB achieved clearance in a mean of 88 days, compared with 58 days for those receiving three treatments a week. Supports that maintenance therapy, once psoriasis has cleared, can continue as a taper or as an indefinite treatment every one to two weeks. Supports a grade-B recommendation for combining acitretin with PUVA. Cites one 60-patient trial of severe psoriasis in which 96 percent cleared with combined PUVA plus acitretin, compared with 80 percent on PUVA alone, using a 43 percent lower cumulative UVA dose in the combination group. Supports that acitretin can also be combined with broadband UVB for generalized plaque psoriasis, clearing patches more rapidly than UVB monotherapy with a lower required cumulative UVB dose. The full article text could not be fetched directly (blocked to automated retrieval); these figures were cross-verified via independently converging secondary reporting of the published guideline rather than read directly from the publisher page.
What it does not support
Does not predict an individual reader’s clearance timeline or guarantee any specific outcome, and does not itself state a retail cost. The acitretin-combination trial is a single 60-patient study, not a larger pooled result. It does not establish the same benefit for narrowband UVB specifically; the broadband-UVB combination finding is reported separately, without the same trial-level statistic. Acitretin carries its own pregnancy contraindication and monitoring needs that this source does not detail.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- PMC (National Library of Medicine)Systematic review · Clinical research, tier 2Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a pooled PASI75 response rate of 70.5% (95% CI 65-75%) from nine studies of narrowband UVB in psoriasis, covering roughly 1,334 participants with Fitzpatrick skin types III through V, mostly from Asia. Supports that studied regimens ranged from twice weekly for eight weeks to three times weekly for twelve weeks. Supports that one included study reached 93.3% target plaque clearance by 12 weeks when narrowband UVB was combined with topical tacalcitol. Supports that another study reported a mean time to clearance of about 32 days when combined with topical tazarotene. Supports post-treatment hyperpigmentation as a reported consideration in darker skin tones, and notes that reduced visibility of erythema in some skin of color patients may lead to underreporting of side effects.
What it does not support
Does not report data on skin cancer risk or long-term safety monitoring, and does not report outcomes for Fitzpatrick I-II skin. Its pooled response rate should not be read as a prediction for every skin tone or population.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.